After raising $1 billion in two private rounds, Kylera is heading to the public markets to step into one of the most expensive biotech races.
Kailera Therapeuticsone of the biggest biotech funds of the past year, is now gearing up for an IPO as it seeks more money to advance its obesity drug pipeline.
Kylera’s movement says this is no longer just a red-hot drug category, but one of the defining investment stories in modern medicine — where the science is promising, the commercial advantage is huge, and the cost of staying competitive can run into the hundreds of millions of dollars before a product reaches the market.
The Massachusetts-based biotech started in 2024 with rights outside of China to four GLP-1-based therapeutics. Jiangsu Hengrui Pharmaceuticals. It also brought in CEO Ron Reno, whose resume carries weight in both Wall Street and biotech circles. Renaud previously led Cerevel Therapeutics before its $8.7 billion acquisition by AbbVie.
Kylera is now trying to turn the early momentum into something more sustainable, and public investors can in turn decide whether that momentum needs support.
In private biotech, a $400 million Series A would already be significant. Kailera followed that up with a $600 million Series B in 2025, making it one of the second largest joint raises of the year.
In most industries, this kind of cash would look like a castle; in the development of obesity drugs, it looks more like a runway.
Kylera had $652.7 million in cash and accumulated deficit of $368.7 million at the end of 2025, according to a new filing with the Securities and Exchange Commission. The company also said it expects to “continue to incur significant costs and recognize operating losses for at least the next several years” as it pushes its candidates through clinical trials and regulatory approval (1).
In obesity, even companies that get eye-watering funds are still finding more and more needs. This is partly because the field has changed so quickly. A few years ago, just having a promising weight loss pill could set you apart. Now its level is very high. Investors want more than early performance. Doctors ultimately want to prove that a drug meets the needs of real patients. Payers want evidence that the benefits justify the costs. And all this requires time, information and money.
Ribupatide, also known as KAI-9531, is the centerpiece, but the pressure is real. The company makes it in two forms: a once-weekly injection and a daily oral tablet. This strategy is important in two ways. If today’s obesity market has taught biotech anything, it’s that convenience is not a side issue. It is part of the product.
The injectable version is already in global phase 3 trials. In a late-stage trial last year in China, Hengrui linked ribupatide to an average weight loss of about 18% at 48 weeks. Previously reported data from an 8 mg study looked even stronger, with participants losing an average of 23.6% body weight at week 36, compared to 1.8% on placebo.
This is an amazing result. Losing about a quarter of your body weight isn’t the kind of change we used to associate with a pill or an injection. It’s a type of change that was once considered mostly in the context of bariatric surgery or drastic medical intervention.
Kylera said ribupatide was designed to have a better clinical profile than Eli Lilly’s Zepbound. But in its filing with the SEC, the company acknowledged that it has yet to conduct a head-to-head trial against an approved obesity drug.
This is not a small comment. In today’s obesity race, posting strong numbers in isolation is one thing. This is another proof that you can outperform the market leader in a direct comparison. Until that happens, the boldest claims remain wishful thinking.
The oral version can be a real opening
If injectable ribupatide is the current flagship, the pill version may be where the wider market starts to gain more interest.
In February, Kylera and Hengrui reported positive phase 2 data from a Chinese trial of oral ribopatide in 166 adults living with obesity. At week 26, participants taking the drug achieved an average weight loss of 12.1%, compared to 2.3% on placebo (2). But the more interesting detail is that “no plateau was observed in weight loss”.
This means that the patients continued to decline by the end of the study, rather than clearly leveling off. Think of it as a car that has not yet reached cruising speed. This suggests that there is still momentum left, although longer studies are needed to determine how much.
At the 25 mg dose, 59.1% of participants lost at least 10% of their body weight, while 38.6% lost at least 15%. Vomiting was reported in 11.4% of participants at 25 mg and 7.5% at 50 mg. Most side effects were described as mild to moderate and mainly gastrointestinal, with no frequent discontinuations or dose reductions due to nausea, vomiting, diarrhea, or constipation.
Dr. Scott Wasserman, Kylera’s Chief Medical Officer, said the results show a “potentially transformative clinical profile” for the treatment of oral obesity. It’s not hard to see why the company relies on the word-of-mouth angle. If injections opened the cycle of modern obesity, pills can extend it.
Not everyone wants to have one injection a week. Not every healthcare system is built to support injection therapy at scale. And not every patient sees himself as someone who is ready for drugs, which psychologically or practically feels like a big medical step. The pill can lower this barrier. It makes it potentially more scalable.
Why public markets and why now?
Kailera has not yet said how many shares it plans to offer or at what price. But the fact is that it is now moving towards an IPO. There is persistent concern about whether biotech IPO windows can remain open amid global market volatility. A company like Kylera stepping forward shows that there is still enough confidence (or at least enough urgency) in obesity to test this hypothesis.
Being obese is dangerous. Competitors are advancing rapidly. Major players like Eli Lilly and Novo Nordisk already dominate the public conversation. Smaller biotechs look to find the next difference, whether it’s greater weight loss, fewer side effects, better tolerability, better muscle retention, oral delivery, or broader cardiometabolic benefits.
Kylera’s IPO plan sounds less like a victory lap and more like a practical recognition of what the category now requires: if you want a real shot at relevance, you need enough capital to stay in the game after the headlines.
This is where the story is bigger than obesity… and has more to do with longevity. Obesity is often treated as an independent condition, but in the science of aging it is better understood as a force multiplier. It increases the likelihood of metabolic disease, cardiovascular disease, fatty liver disease, chronic inflammation, loss of mobility, and a shorter lifespan. It can accelerate the type of biological wear and tear that makes later life harder, more fragile, and more expensive.
These drugs are more important than the joke trimesters. Yes, the market is very hot in places. Yes, some companies overpromise. And yes, investors should be careful when a biotech talks about “outperformance” without direct comparative data. However, the deeper trend is that obesity treatment is increasingly becoming part of the infrastructure of preventive medicine and healthy aging.
Kylera’s IPO plans are evidence that the field is becoming something bigger than a blockbuster drug race. If these treatments continue and become more accessible, tolerable, and adaptable to different patients, they may do more than just help people lose weight.
Photo: GoldenDayz/Envato
(1) https://www.fiercebiotech.com/biotech/kailera-plots-ipo-fund-obesity-pipeline-after-one-biggest-raises-2025
(2) https://www.kailera.com/press-release/kailera-therapeutics-and-hengrui-pharma-report-positive-topline-data-from-phase-2-obesity-trial-of-oral-ribubatide/
